BWXT Medical Enters into a New Long-Term Agreement with Boston Scientific for the Manufacture of TheraSphere™ Y-90 Glass Mi...
May 10 2021 - 6:45AM
Business Wire
BWXT Medical Ltd. (BWXT Medical) announced today that it has
entered into a new long-term, mutually exclusive agreement to
manufacture TheraSphere™ Y-90 Glass Microspheres for Boston
Scientific, a leading global medical device company.
Developed for the treatment of patients with hepatocellular
carcinoma (HCC), TheraSphere treatment is comprised of millions of
glass microspheres containing radioactive Yttrium-90, which are
delivered directly to liver tumors via catheter and result in
minimal exposure to surrounding healthy tissue.
BWXT Medical is a subsidiary of BWX Technologies, Inc. (NYSE:
BWXT) and a global supplier of medical isotopes and
radiopharmaceuticals.
Under the terms of the agreement, BWXT Medical will invest to
automate the production process at its Ottawa, Canada facility, and
thereby significantly increase capacity and dependability to
support a growing global demand for TheraSphere.
“We congratulate Boston Scientific on its recent receipt of FDA
PMA approval of TheraSphere, which expands patient access to this
unique technology,” said Martyn Coombs, president of BWXT Medical.
“We share the aspiration of making a significant difference in the
lives of people suffering with cancer, and we look forward to
continuing to build a strong supply chain foundation for future
growth.”
Forward Looking Statements
BWXT cautions that this release contains forward-looking
statements, including statements relating to expectations for the
production, performance, demand, timing and impact of TheraSphere.
These forward-looking statements involve a number of risks and
uncertainties, including, among other things, changes in market
demand, delays in automation of our production, regulatory
approvals and competitive actions. If one or more of these or other
risks materialize, actual results may vary materially from those
expressed. For a more complete discussion of these and other risk
factors, please see BWXT’s annual report on Form 10-K for the year
ended December 31, 2020 and subsequent quarterly reports on Form
10-Q filed with the Securities and Exchange Commission. BWXT
cautions not to place undue reliance on these forward-looking
statements, which speak only as of the date of this release, and
undertakes no obligation to update or revise any forward-looking
statement, except to the extent required by applicable law.
About BWXT
At BWX Technologies, Inc. (NYSE: BWXT), we are People Strong,
Innovation Driven. Headquartered in Lynchburg, Va., BWXT provides
safe and effective nuclear solutions for national security, clean
energy, environmental remediation, nuclear medicine and space
exploration. With approximately 6,700 employees, BWXT has 12 major
operating sites in the U.S. and Canada. In addition, BWXT joint
ventures provide management and operations at more than a dozen
U.S. Department of Energy and NASA facilities. Follow us on Twitter
at @BWXTech and learn more at www.bwxt.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210510005041/en/
BWXT Media Contact Natalie Cutler Director,
Communications, BWXT Canada Ltd. 519-620-5288 nacutler@bwxt.com
BWXT Investor Contact Mark Kratz Vice President, Investor
Relations 980.365.4300 investors@bwxt.com
BWX Technologies (NYSE:BWXT)
Historical Stock Chart
From Mar 2024 to Apr 2024
BWX Technologies (NYSE:BWXT)
Historical Stock Chart
From Apr 2023 to Apr 2024